The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets
- 1 February 1994
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 120 (4) , 204-207
- https://doi.org/10.1007/bf01372557
Abstract
The antiemetic activity of granisetron was examined in ferrets aged 10–13 weeks. Emesis was induced by exposure to either whole-body X-irradiation (50 Gy over 10.4 min) or cyclophosphamide (80 mg/kg i.v.) plus doxorubicin (6 mg/kg i.v.). Following exposure to whole-body X-irradiation, the young ferrets vomited with a similar latency to vomit and severity of emesis to that shown by adult animals. Granisetron (0.5 mg/kg i.v.) significantly reduced (P≤0.05) the number of vomits and retches and two out of four animals were completely protected. Following injection of cyclophosphamide and doxorubicin, the young ferrets showed a reduced emetic, response compared to adult animals. Following a dose of granisetron (0.5 mg/kg i.v.), only one out of four ferrets vomited compared to four out of four in the control group. Further experiments showed that cisplatin (12.5 mg/kg i.v.) was unable to induce vomiting in the young ferret (n=2). Granisetron (0.5 mg/kg i.v.) was well tolerated by the young ferret and was able to reduce significantly or completely abolish emesis induced by cytostatic treatment. The data support the use of granisetron in pediatric patients and clinical trials are currently underway in this patient population.Keywords
This publication has 17 references indexed in Scilit:
- Further Studies of the Antiemetic Activity of Granisetron against Whole Body X-lrradiation or Cisplatin-lnduced Emesis in the FerretPharmacology, 1994
- Are all 5-HT3 receptor antagonists the same?European Journal Of Cancer, 1992
- The concept of selectivity in 5-HT receptor researchEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.1990
- Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron)European Journal of Pharmacology, 1989
- The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.BMJ, 1988
- Dexamethasone as an Antiemetic in Children Receiving cis-PlatinumJournal of Pediatric Hematology/Oncology, 1988
- The Management of Chemotherapy-Induced Nausea and VomitingMedical Clinics of North America, 1987
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- The effectiveness of behavioral intervention for reduction of nausea and vomiting in children and adolescents receiving chemotherapy.Journal of Clinical Oncology, 1984